Tuesday, April 16, 2024

Health Technology Council to Evaluate Transcranial Magnetic Stimulation for Treatment-Resistant Depression

Similar articles

In a significant development for the field of mental health, the Health Technology Council has initiated an evaluation process to determine the viability of using Transcranial Magnetic Stimulation (TMS) as a treatment option for adult patients suffering from treatment-resistant depression. This groundbreaking assessment, launched on October 5, 2023, aims to provide crucial insights into the potential benefits of TMS therapy and its role in addressing a challenging mental health condition.

The Health Technology Council, established in 2021, has a core mission of promoting the widespread adoption of cost-effective healthcare technologies. To accomplish this goal, the council issues recommendations to healthcare regions and hospitals. Two primary types of reports are generated: evaluations and major analyses. Both follow a structured process, including proposal, evaluation/analysis, decision, and implementation.

However, it’s important to note the distinctions between these report types. Annually, the council undertakes 2-3 ‘major analyses’ that delve into fundamental topics, such as treatment regimens and approaches to treatment organization, proposed by hospitals or regions (not industry). In contrast, the council has the capacity to conduct 15-25 ‘evaluations’ annually, specifically focused on already marketed medical devices and health technologies. These evaluations are open to proposals from all stakeholders, including industry representatives.

The expected publication date for the evaluation on TMS as a treatment option for treatment-resistant depression has not been disclosed as of yet. Nonetheless, this development holds significant promise for individuals who have not responded well to traditional depression treatments.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article